In pharmaceuticals and biotechnology, “the pipeline” refers to the entire sequence of stages a new drug must pass through before it reaches patients. It starts with early laboratory research and ends with regulatory approval and ongoing safety monitoring. The full journey typically takes 7 to 10 years, costs an estimated $879 million per successful drug (accounting for failures and capital costs), and only about 14% of compounds that enter the first phase of human testing ever make it to approval.
Understanding the pipeline matters whether you’re a patient waiting on a promising treatment, an investor evaluating a biotech company, or simply someone curious about why new medicines take so long to arrive. Each stage serves a specific purpose, and drugs can fail at any point along the way.
Discovery and Preclinical Research
Every drug begins in the laboratory. Scientists first identify a biological “target,” usually a protein or gene involved in a disease. They then screen thousands of chemical compounds to find ones that interact with that target in a useful way. This process involves cell-based experiments and computer modeling to narrow down candidates from potentially millions of molecules to a handful worth pursuing.
Once researchers have a promising compound, it moves into preclinical research: testing in laboratory settings and animal models to answer basic questions about safety. Does it cause organ damage? How does the body absorb and break it down? What dose causes toxic effects? Animal studies also provide early clues about whether the drug actually works against the disease. Compounds that prove too toxic or ineffective are dropped here, before any human is ever exposed. This discovery and preclinical phase alone can take several years.
Phase I: First Tests in Humans
Phase I is the first time a drug is given to people. These trials are small, typically involving 20 to 80 participants, often healthy volunteers. The goal is not to cure anyone but to establish safety. Researchers start with a very low dose in a small group and watch closely for side effects over a defined period. If that group tolerates the drug, the next group receives a slightly higher dose. This escalation continues until researchers identify the maximum tolerated dose.
Phase I trials also measure how the drug moves through the body: how quickly it’s absorbed, how long it stays active, and how it’s eliminated. Because so few people participate, rare side effects often go undetected at this stage. They may not surface until hundreds or thousands of patients have taken the drug in later phases.
Phase II: Does the Drug Actually Work?
Phase II trials expand the pool to a few hundred patients who have the disease the drug is meant to treat. The central question shifts from “is this safe?” to “does this show enough promise to justify a large, expensive trial?” Researchers measure whether the drug produces a meaningful therapeutic effect and continue gathering safety data.
These trials also help refine the optimal dose and dosing schedule. They generate information about which specific patient populations respond best, what side effects look like in real patients, and how manageable those side effects are. A drug that clears Phase II has preliminary evidence of efficacy, but that evidence isn’t yet definitive.
Phase III: Large-Scale Proof
Phase III trials are the pivotal studies that regulators rely on most heavily. They enroll a much broader population, often hundreds to thousands of patients across multiple locations, and run for a longer period. The drug is typically compared head-to-head against either a placebo or the current standard treatment to determine whether it offers a real benefit.
These trials are expensive, logistically complex, and often the stage where promising drugs fail. A compound might show a modest benefit that doesn’t outweigh its side effects, or it might not outperform existing treatments by enough to matter. Recruiting enough eligible patients willing to participate is one of the biggest practical challenges. Phase III results form the backbone of the application a company submits to regulators.
Regulatory Review and Approval
After successful Phase III trials, the drug’s developer submits a New Drug Application (NDA) to the FDA (or equivalent agencies in other countries). This document tells the drug’s complete story: clinical trial results, animal study data, details about ingredients, how the drug behaves in the body, and how it’s manufactured, processed, and packaged. The FDA uses this information to determine three things: whether the drug is safe and effective for its proposed use, whether the benefits outweigh the risks, and whether the labeling accurately describes what doctors and patients need to know.
Regulatory review itself is a substantial time commitment. By one estimate, regulatory administration alone accounts for over three years of the total development timeline. Companies pay user fees to support the review process, and the FDA follows standardized procedures to evaluate each application. Not every submission is approved on the first attempt; the agency may request additional data or modifications.
Phase IV: Monitoring After Approval
Approval is not the end of the pipeline. Phase IV refers to the ongoing surveillance that continues for as long as a drug is on the market. Side effects that occur in fewer than 1 in 3,000 to 5,000 patients are unlikely to be detected during clinical trials, simply because not enough people participated. These rare reactions only surface once large numbers of real-world patients are taking the drug.
Pharmaceutical companies maintain global systems to track, investigate, and evaluate reports of adverse events from doctors and patients. When a physician files an adverse event report, that data feeds into a worldwide monitoring effort. If new safety signals emerge, regulators can require changes to the drug’s labeling, add new warnings, restrict its use, or in serious cases, pull it from the market entirely. Regulatory authorities may also require post-marketing studies to verify the drug’s safety and effectiveness in specific populations that weren’t well represented in the original trials.
Why Most Drugs Never Make It
The pipeline is designed to be a filter, and it filters aggressively. A large-scale analysis of 2,092 compounds and nearly 20,000 clinical trials conducted by 18 major pharmaceutical companies between 2006 and 2022 found that the average likelihood of a drug going from Phase I to first FDA approval was 14.3%. That rate varied considerably by company, ranging from about 8% to 23%, but even the best performers saw the vast majority of their candidates fail.
Previous industry benchmarks had placed the overall success rate even lower, around 10%. Drugs fail for many reasons: unexpected toxicity, lack of efficacy in larger populations, manufacturing difficulties, or simply being no better than what’s already available. This high failure rate is a major reason drug development is so expensive. The $879 million average cost per successful drug includes the money spent on all the compounds that didn’t make it. Out-of-pocket spending per drug averages about $173 million, but factoring in the cost of failures and the capital tied up over a decade of development roughly quintuples that figure.
The Pipeline at a Glance
- Discovery and preclinical: Laboratory and animal testing to identify and validate a drug candidate
- Phase I: Safety and dosing in 20 to 80 people
- Phase II: Early efficacy testing in a few hundred patients
- Phase III: Large-scale trials comparing the drug to existing treatments or placebo
- Regulatory review: FDA evaluation of the complete data package
- Phase IV: Ongoing safety monitoring after the drug reaches the market
When a biotech company says it has “a strong pipeline,” it means it has multiple drug candidates at various stages of this process. A pipeline heavy with Phase III candidates is closer to potential revenue. One dominated by early-stage compounds faces years of uncertainty. The term has become shorthand not just for the process itself but for a company’s portfolio of future possibilities, each one a bet that a molecule discovered in the lab will survive every stage and eventually help a patient.